| Literature DB >> 35889152 |
Igor Dumic1,2, Dorde Jevtic3,4, Mladjen Veselinovic5, Charles W Nordstrom1,2, Milan Jovanovic6, Vanajakshi Mogulla1,2, Elmira Mofid Veselinovic7, Ann Hudson1,2, Gordana Simeunovic8, Emilia Petcu1,2, Poornima Ramanan9.
Abstract
Anaplasma phagocytophilum is an emerging, Gram-negative, obligate intracellular pathogen that is transmitted by a tick vector. Human infection ranges from asymptomatic to severe disease that can present with pancytopenia, multiorgan failure, and death. The aim of this systematic review is to analyze case reports and case series reported over the last two decades in peer-reviewed journals indexed in the Medline/PubMed database according to the PRISMA guidelines. We found 110 unique patients from 88 case reports and series. The most common mode of transmission was tick bite (60.9%), followed by blood transfusion (8.2%). Infection was acquired by blood transfusion in nearly half (42%) of the immunocompromised patients. Most patients reported fever (90%), followed by constitutional (59%) and gastrointestinal symptoms (56%). Rash was present in 17% of patients, much higher than in previous studies. Thrombocytopenia was the most common laboratory abnormality (76%) followed by elevated aspartate aminotransferase (AST) (46%). The diagnosis was most commonly established using whole-blood polymerase chain reaction (PCR) in 76% of patients. Coinfection rate was 9.1% and Borrelia burgdorferi was most commonly isolated in seven patients (6.4%). Doxycycline was used to treat 70% of patients but was only used as an empiric treatment in one-third of patients (33.6%). The overall mortality rate was 5.7%, and one patient died from trauma unrelated to HGA. The mortality rates among immunocompetent and immunocompromised patients were 4.2% (n = 4/95) and 18.2% (n = 2/11), respectively. Four of the six patients who died (66.6%) received appropriate antibiotic therapy. Among these, doxycycline was delayed by more than 48 h in two patients.Entities:
Keywords: Anaplasma phagocytophilum; Borrelia burgdorferi; anaplasmosis; coinfection; human granulocytic anaplasmosis; tick borne disease; ticks
Year: 2022 PMID: 35889152 PMCID: PMC9318722 DOI: 10.3390/microorganisms10071433
Source DB: PubMed Journal: Microorganisms ISSN: 2076-2607
Figure 1PRISMA flow chart.
Comorbid conditions of immunocompetent patients and cause for immunosuppression in immunocompromised patients.
| Comorbid Conditions of Immunocompetent Patients | Number of Patients (%) | Cause for Immunosuppression in Immunocompromised Patients | Number of Patients (%) |
|---|---|---|---|
| Hypertension | 9 (8.2) | Steroid use; DM | 5 (4.5) |
| Hypothyroidism; CAD | 6 (5.5) | CKD | 4 (3.6) |
| Joint disease | 5 (4.5) | Hematologic malignancies; Cytotoxic medication | 3 (2.7) |
| Smoking; HLP; Malignancy | 4 (3.6) | Asplenia | 1 (0.9) |
| BPH; COPD; Inherited hematologic abnormality | 3 (2.7) | ||
| Hematologic malignancy in remission; HF; Ischemic cardiomyopathy | 2 (1.8) | ||
| Other less common comorbidities (hydrocephalus, kidney transplant, A-fib, gynecomastia, depression, Chrons disease, valve replacement, aortic aneurysm, sleep apnea, ureter stones, diverticulosis, colectomy, gunshot wound, SVT, fungal sinusitis, gastritis, hip fracture, fibromyalgia, TIA, embolic stroke, carpal-tunnel syndrome, rhabdomyolysis, Stevens–Johnson syndrome, asthma) | 1 (0.9) | ||
CAD—coronary artery disease, HLP—hyperlipidemia, BPH—benign prostatic hyperplasia, COPD—chronic obstructive pulmonary disease, HF—heart failure, A-fib—atrial fibrillation, SVT—supraventricular tachyarrhythmia, TIA—transitory ischemic attack, DM—diabetes mellitus, CKD—chronic kidney disease.
Figure 2(A) List of countries where the case reports originated. (B) Number of article years.
Clinical manifestations of the patients diagnosed with HGA.
| Symptom | Number of Cases (%) | |
|---|---|---|
| Fever | 99 (90) | |
| Constitutional symptoms | 65 (59.1) | |
| GI symptoms | Diarrhea | 20 (18.2) |
| Nausea | 16 (14.5) | |
| Abdominal pain | 10 (9.1) | |
| Anorexia | 8 (7.3) | |
| Emesis | 7 (6.4) | |
| Myalgia | 46 (41.8) | |
| Headache | 41 (37.3) | |
| Chills | 35 (31.8) | |
| Arthralgia | 25 (22.7) | |
| Rash | 19 (17.3) | |
| AKI | 17 (15.5) | |
| Cough | 10 (9.1) | |
| Splenic complications | Splenomegaly | 10 (9.1) |
| Splenic rupture | 1 (0.9) | |
| Splenic infarct | 1 (0.9) | |
| Confusion | 9 (8.2) | |
| Diaphoresis | 8 (7.3) | |
| SOB/Respiratory distress | 7 (6.4) | |
| Dizziness | 3 (2.7) | |
| Rigor | 2 (1.8) | |
HGA—human granulocytic anaplasmosis, GI—gastrointestinal, AKI—acute kidney injury, SOB—shortness of breath.
Laboratory investigations and laboratory abnormalities reported in patients diagnosed with HGA.
| Parameter | Mean (SD) | Parameter | Number of Patients (%) | |
|---|---|---|---|---|
| Hb ** (g/dL) | 12.7 (1.8) | Anemia (<12 g/dL in women, <13 g/dL in men) | 33 (30) | |
| Platelets ** (×10 (9)/L) | 72 (6.6) | Thrombocytopenia (<150 × 10 (9)/L) | 79 (71.8) | |
| WBC ** (×10 (9)/L) | 4.8 (0.5) | Leukopenia (<4 × 10 (9)/L) | 51 (46.4) | |
| BUN * (mg/dL) | 50.1 (8.3) | |||
| Creatinine * (mg/dL) | 3.3 (0.4) | |||
| Bilirubin * (mg/dL) | 2.3 (0.5) | |||
| AST * (U/L) | 162.6 (19.7) | LFT abnormalities | AST (>40 U/L) | 63 (57.3) |
| ALT * (U/L) | 107.5 (11.1) | ALT (>50 U/L) | 53 (48.2) | |
| ALP * (U/L) | 148.4 (23.3) | ALP (>150 U/L) | 7 (6.4) | |
| Na ** (mmoL/L) | 132.4 (3.1) | |||
| LDH * (U/L) | 911.8 (198.5) | |||
| CRP * (mg/dL) | 148.1 (14.2) | Inflammation | ESR (>29 mm/h in women, >22 mm/h in men) | 13 (11.8) |
| ESR * (mm/hr) | 52.1 (7.4) | CRP (>10 mg/L) | 37 (33.6) | |
| Ferritin * (ng/mL) | 12,076 (6820) | |||
* Highest value reported; ** Lowest value reported; HGA—human granulocytic anaplasmosis, Hb—hemoglobin, WBC—white blood cells, BUN—blood urea nitrogen, AST—aspartate aminotransferase, ALT—alanine aminotransferase, ALP—alkaline phosphatase, LDH—lactate dehydrogenase, CRP—C reactive protein, ESR—erythrocyte sedimentation rate, LFT—liver function test.